Fate Therapeutics
FATEFATE · Stock Price
Historical price data
Overview
Fate Therapeutics is on a mission to deliver 'Better Cells for Better Therapies®' by leveraging its industry-leading induced pluripotent stem cell (iPSC) platform to create off-the-shelf, uniformly engineered cell products. The company has established a broad clinical pipeline targeting hematologic malignancies, solid tumors, and autoimmune disorders, with multiple programs in Phase 1/2 development. Its core strategy is to disrupt the cell therapy paradigm by moving from bespoke, patient-specific manufacturing to a scalable, industrialized model that promises greater consistency, lower cost, and immediate patient access.
Technology Platform
Proprietary induced pluripotent stem cell (iPSC) platform enabling the creation of clonal master cell lines for the mass production of uniform, multiplexed-engineered, off-the-shelf cellular immunotherapies.
Pipeline
21| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ProHema-CB + Untreated CB | Hematologic Malignancies | Phase 2 | |
| ProTmune + Control Arm | Hematologic Malignancies | Phase 1/2 | |
| Single FT1050 treated UCB unit | Non-Hodgkin's Lymphoma (NHL) | Phase 1 | |
| ProHema-CB Transplant | Metabolic Disorders | Phase 1 | |
| FT516 + Rituximab + Obinutuzumab + Cyclophosphamide + Fludar... | Acute Myelogenous Leukemia | Phase 1 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Fate competes directly with other allogeneic cell therapy developers (e.g., Allogene, CRISPR Therapeutics) and must ultimately demonstrate superiority or parity to approved autologous CAR-T products from large pharma. Its iPSC platform is a key differentiator, but it must prove clinical efficacy and persistence to secure a competitive advantage.